Camurus AB (FRA:7CA) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7CA Camurus AB FRA:7CA
81 GF Score
Price €55.45
GF Value €61.13
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Camurus AB Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:7CA
81GF Score
Camurus AB FRA:7CA
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Camurus AB (FRA:7CA) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of €55.45 is trading 9.3% below its estimated GF Value™ of €61.13. GuruFocus considers Camurus AB to be Fairly Valued.

Key valuation signals for FRA:7CA:

  • Dividends Received:
  • GF Value™: €61.13 vs. price of €55.45 (9.3% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the FRA:7CA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score

Get the complete analysis for FRA:7CA

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€55.45
Price
€61.13
GF Value